Orano - Annual Activity Report 2025 44 2 SITUATION AND ACTIVITIES OF THE COMPANY AND ITS SUBSIDIARIES DURING THE PAST FINANCIAL YEAR The group’s businesses Source: Orano Engineering that is eco-responsible, ethical and 4.0 compliant to better serve its customers Process engineering Attending to the customer's expectations through the design and construction of high-performance facilities. Design and construction engineering Supporting the customer throughout the whole project, from feasibility to construction. Dismantling engineering Assisting the customer to help them design and manage dismantling projects for complex facilities. Advice and expertise Offering at disposal a plurality of disciplines and specialist know-how to feed technical and economic optimization. Project management Managing multi-dimensional projects. Support engineering for the operator Being present on the ground with the customer and providing on-site assistance (maintenance, in-service support). Aval du Futur program The Aval du Futur program is in line with the decisions of the Nuclear Policy Councils (NPCs) of February 26, 2024 and March 17, 2025, held under the aegis of the President of the French Republic. The latter confirmed the national treatment-recycling strategy for fuels from current and future nuclear power plants and approved the renewal of treatment-recycling plants. These decisions take the form of: ● extending the life of the la Hague and Melox plants beyond 2040 (“Life extension and resilience program”, see Section 2.1.2.3); ● launching studies for the construction of a new MOX recycled fuel manufacturing plant at the la Hague site; and ● launching studies for the construction of a new spent fuel processing plant on the la Hague site by 2045/2050 (Aval du Futur program). 2.3.4 Other activities of Orano Orano’s other activities include the other cross-business functions, as well as Nuclear Medicine. Nuclear Medicine Orano’s Nuclear Medicine business is mainly carried out by Orano Med, its medical subsidiary. It is developing a new generation of targeted therapies against cancer thanks to the unique properties of lead-212 (212Pb), a particularly rare alpha-emitting radioisotope with a potent cytotoxic action. By combining lead-212 with molecules capable of targeting tumor cells, Orano Med is participating in the development of an innovative approach called targeted alpha-therapy. It can recognize and destroy cancer cells selectively, limiting the impact on surrounding healthy cells. The biotechnology company has also developed a unique process to extract and produce 212Pb at a very high level of purity, as well as industrial facilities that are unique in the world, dedicated to the large-scale production of lead-212 radiolabeled treatments, in France and the United States.
RkJQdWJsaXNoZXIy NzMxNTcx